Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1749 results about "Eye disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A condition that affects any of the eye components such as cornea, iris, pupil, optic nerve, lens, retina, macula, choroid, conjunctiva or the vitreous.
Ocular implant with anchor and multiple openings
An implant for treating an ocular disorder has a longitudinal implant axis, an outflow portion passing therethrough, a plurality of longitudinally spaced openings therein, an inflow portion, and an anchoring member that extends from the implant and is disposed distally of the openings. The outflow portion is shaped and sized to be introduced into Schlemm's canal of an eye at an angle, and received at least partially within Schlemm's canal regardless of its rotational orientation about the axis during introduction. The openings allow fluid communication from a lumen within the outflow portion to a location outside the outflow portion. The inflow portion is configured to be positioned within an anterior chamber of the eye to permit fluid communication from the anterior chamber to the outflow portion. The axis extends through a trabecular meshwork of the eye and is generally orthogonal to Schlemm's canal during the fluid communication.
Owner:GLAUKOS CORP
Ocular implant with therapeutic agents and methods thereof
InactiveUS7708711B2Simple treatmentPromote recoveryEye surgeryAnaesthesiaAqueous humorOcular implant
Devices and methods are provided for the treatment of ocular disorders. An ocular implant has a body comprising material that includes a therapeutic drug. The body has an inlet portion and an outlet portion. The inlet portion is configured to reside in an anterior chamber of an eye when the outlet portion is disposed in a physiological outflow pathway of the eye. The outlet portion has an outflow opening such that the body drains fluid from the anterior chamber to the physiological outflow pathway. One method of treating an ocular disorder involves introducing an implant comprising a therapeutic drug into the eye such that the implant drains aqueous humor into a physiological outflow pathway and the therapeutic drug reaches eye tissue.
Owner:DOSE MEDICAL CORP
Janus kinase inhibitors for treatment of dry eye and other eye related diseases
InactiveUS20100113416A1High expressionIncrease productionBiocideOrganic active ingredientsDiseaseOcular disease
Owner:INCYTE
Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same
InactiveUS6379712B1Improve solubilityPreventing mold build-upPowder deliveryOrganic active ingredientsEscherichia coliDisease
The present invention relates to nanosilver-containing antibacterial and antifungal granules ("NAGs"). The NAGs have longlasting inhibitory effect on a broad-spectrum of bacteria and fungi, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C. The NAGs contain ground stalk marrow of the plant Juncus effusus L. which has been dispersed with nanosilver particles. The nanosilver particles are about 1-100 nm in diameter. Each of the nanosilver particles contain a metallic silver core which is surrounded by silver oxide. The present invention also provides a process for making the NAGs. The NAGs can be used in a variety of healthcare and industrial products. Examples of the healthcare products include, but are not limited to, ointments or lotions to treat skin trauma, soaking solutions or cleansing solutions for dental or women hygiene, medications for treating gastrointestinal bacteria infections, sexual related diseases, and eye diseases. Examples of industrial products include, but are not limited to, food preservatives, water disinfectants, paper disinfectants, construction filling materials (to prevent mold formation).
Owner:LEGEND WIN FINANCE
Diagnostic, Prescriptive, and Data-Gathering System and Method For Macular Pigment Deficits and Other Eye Disorders
ActiveUS20100241450A1Compact and inexpensive and well-suited for placement and operationInexpensive and convenientDrug and medicationsNutrition controlPatient dataMedical prescription
A macular health measurement and storage system comprises a plurality of macular-pigment measurement machine for measuring macular pigment density in humans, a plurality of computers each of which is associated with a corresponding one the macular-pigment measuring machines, and a central host. The plurality of macular-pigment measurement machines include a device for receiving macular pigment data from a patient, at least one data transfer port, and at least one processor that enables the transfer of the macular pigment data from the transfer port. The plurality of computers include a first port coupled to the data transfer port of the corresponding macular-pigment measurement machine for receiving the macular pigment data. Each of the computers includes a second port for transferring patient data. The central host is coupled to the second ports on each of the plurality of computers. The central host includes a storage device for storing the patient data.
Owner:ZEAVISION LLC
Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
InactiveUS20120283557A1Short pulse durationLaser surgerySurgical instrument detailsDiseaseFemto second laser
Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be effected under gonioscopic control. Internal delivery may he controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.
Owner:BERLIN MICHAEL S
Therapeutic uses of inhibitors of RTP801
InactiveUS7741299B2Effect minimizedMinimize ToxicitySenses disorderNervous disorderTreatment useCancer research
Owner:QUARK FARMACUITIKALS INC
Wearable photoactivator for ocular therapeutic applications and uses thereof
The invention provides a wearable device for delivery of light of a desired wavelength and power to the cornea of a subject. The device includes a frame for attachment of a light source housing which includes a light source and a lens positioned in the housing to allow light to be directed to the eye of the subject, and the light source is operably linked to a power source. The invention provides method for the prevention and treatment of ocular disease including infection, neoplasia, and corneal dystrophies. The device of the invention can be used in conjunction with photoactive therapeutic agents.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
Owner:CHIRON CORP +1
Drug delivery systems and use thereof
InactiveUS20050175708A1Reduced inhibitory activityTreat and inhibit diseasePowder deliveryBiocideVascular endothelial growth factorDelivery system
The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration.
Owner:MASSACHUSETTS EYE & EAR INFARY
Systems and methods for the treatment of eye conditions
ActiveUS20150057701A1Minimizing amount of energyUltrasound therapyEye surgeryMeibomian glandLight energy
Systems, methods, and devices used to treat eyelids, meibomian glands, ducts, and surrounding tissue are described herein. In some embodiments, an eye treatment device is disclosed, which includes a scleral shield positionable proximate an inner surface of an eyelid, the scleral shield being made of, or coated with, an energy-absorbing material activated by a light energy, and an energy transducer positionable outside of the eyelid, the energy transducer configured to provide light energy at one or more wavelengths, including a first wavelength selected to heat the energy-absorbing material.
Owner:ALCON INC
Dendrimers for sustained release of compounds
Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
Owner:WAYNE STATE UNIV
Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
InactiveUS20050063961A1Stably incorporated into neovasculature of the eyePromote repairBiocideSenses disorderDiseaseProgenitor
Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells in the isolated Lin− HSCs express the cell surface antigen CD31. The isolated Lin− HSC populations are useful for treatment of ocular vascular diseases. In a preferred embodiment, the Lin− HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin− HSC population containing EPCs. Isolated Lin− HSCs that have been transfected with therapeutically useful genes are also provided, and are useful for delivering genes to the eye for cell-based gene therapy. Methods of preparing isolated stem cell populations of the invention, and methods of treating ocular diseases and injury are also described.
Owner:THE SCRIPPS RES INST
Apparatus and methods for prevention of age-related macular degeneration and other eye diseases
InactiveUS20030105456A1Minor side effectsIncrease flexibilityLaser surgerySurgical instruments for heatingRadio frequencyLaser beams
Surgical apparatus and surgical methods are proposed for the prevention of age-related macular degeneration (AMD) and choroidal neovascularization (CNV), and other eye diseases such as glaucoma by removal of the sclera tissue to reduce its rigidity and increase the flood flow and decrease pressure in the choriocapillaris. The disclosed preferred embodiments of the system consists of a tissue ablation means and a control means of ablation patterns and a fiber delivery unit. The basic laser beam includes UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (0.5-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. AMD and CNV are prevented, delayed or reversed by using an ablative laser to ablate the sclera tissue in a predetermined patterns outside the limbus to increase the elasticity of the sclera tissue surrounding the eye globe The surgery apparatus also includes non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device
Owner:LIN J T
Treatment of ocular disease
The invention relates to a novel apparatus for the treatment of ocular disease, particularly glaucoma. The apparatus consists of a locating device to locate Schlemm's Canal within the anterior portion of the eye and a surgical tool to access the canal for treatment. The apparatus allows for guided, minimally invasive surgical access to Schlemm's Canal to enable surgical procedures to be performed on the canal and trabecular meshwork to reduce intraocular pressure. The apparatus may also deliver devices or substances to Schlemm's Canal in the treatment of glaucoma.
Owner:NOVA EYE INC
System and methods for automatic processing of digital retinal images in conjunction with an imaging device
Systems and methods of obtaining and recording fundus images by minimally trained persons, which includes a camera for obtaining images of a fundus of a subject's eye, in combination with mathematical methods to assign real time image quality classification to the images obtained based upon a set of criteria. The classified images will be further processed if the classified images are of sufficient image quality for clinical interpretation by machine-coded and / or human-based methods. Such systems and methods can thus automatically determine whether the quality of a retinal image is sufficient for computer-based eye disease screening. The system integrates global histogram features, textural features, and vessel density, as well as a local non-reference perceptual sharpness metric. A partial least square (PLS) classifier is trained to distinguish low quality images from normal quality images.
Owner:VISIONQUEST BIOMEDICAL
Janus kinase inhibitors for treatment of dry eye and other eye related diseases
InactiveUS20120301464A1High expressionIncrease productionBiocideSenses disorderDiseaseOcular disease
Owner:INCYTE HLDG & INCYTE
Image processing apparatus and image processing method
InactiveUS20110137157A1Efficiently obtainedImage enhancementImage analysisEye stateImaging processing
This invention concerns the acquisition of diagnosis information data effective for diagnosing eye disease independently of the eye state. An image processing apparatus for processing a tomogram of an eye includes a unit configured to determine an eye feature based on the tomogram and thus determine the eye state, a unit configured to detect, from the tomogram, a detection target to be used to calculate diagnosis information data quantitatively representing the determined eye state, and a unit configured to calculate the diagnosis information data using position information of the detection target. In accordance with the eye state, the detection unit changes the detection target or an algorithm to be used to detect the detection target.
Owner:CANON KK
RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
Owner:ALCON RES LTD
6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS
Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
![6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3dc8f53b-639a-4691-adea-803f412a77c0/US20080153813A1-20080626-C00001.png "6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS")
![6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3dc8f53b-639a-4691-adea-803f412a77c0/US20080153813A1-20080626-C00002.png "6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS")
![6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3dc8f53b-639a-4691-adea-803f412a77c0/US20080153813A1-20080626-C00003.png "6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS")
Owner:ALCON RES LTD
Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: ##STR1## or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R.sub.1, R.sub.21, R.sub.22 and R.sub.23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R.sub.22 and R.sub.23, together with the N, form a heterocycle; A.sub.1 and A.sub.2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR.sub.24, CR.sub.25 R.sub.26, C(O), NR.sub.24 C(O), C(O)NR.sub.24, SO, SO.sub.2 or a covalent bond; where R.sub.24, R.sub.25 and R.sub.26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.
Owner:COCENSYS
Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
Particular embodiments disclosed herein relate to electrokinetically altered gas-enriched fluids, methods of making the same, systems for making the same and / or methods of treatment utilizing the gas-enriched fluids for eye related conditions and / or diseases. In certain embodiments, the electrokinetically altered gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and / or therapeutic fluids and / or methods of treatment utilizing the fluids to treat a cosmetic and / or therapeutic symptom related to eye conditions and / or diseases.
Owner:REVALESIO CORP
Therapeutic uses of inhibitors of RTP801
InactiveUS20060217329A1Effect minimizedMinimize ToxicityOrganic active ingredientsSenses disorderDiseaseCancer research
Owner:QUARK FARMACUITIKALS INC
Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
InactiveUS20090269356A1Lower Level RequirementsImprove acuityBiocideSenses disorderDiseaseEye disease
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.
Owner:ARCHEMIX CORP
Anti-angiogenic peptides and methods of use thereof
InactiveUS20060172941A1Low ICHigh affinitySenses disorderPeptide/protein ingredientsBiological activationLeukemia
Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides may be used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.
Owner:SOPHERION THERAPEUTICS
Ocular implant with anchoring mechanism and multiple outlets
Devices and methods for treating ocular disorders are disclosed. One ocular implant, has a substantially straight, rigid, elongate body. The body has a self-trephinating distal portion that narrows toward a distal end, and at least one inlet that communicates with at least one inner lumen that communicates with a plurality of outlets. The lumen has a sufficient length to extend from an anterior chamber of an eye to a physiologic outflow pathway. An anchor member extends from the implant.
Owner:GLAUKOS CORP
Nanosilver-containing antibacterial and antifungal granules and methods for preparing and using the same
Owner:LEGEND WIN FINANCE
Anti-Angiogenic Peptides and Methods of Use Thereof
Owner:SOPHERION THERAPEUTICS
Methods and compositions for treating eye disorders
InactiveUS20040234532A1Efficiently provideAntibacterial agentsBacterial antigen ingredientsUveitisViral Conjunctivitis
The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and / or a Clostridial botulinum.
Owner:ALLERGAN INC
Methods and compositions for treating ophthalmic conditions with retinyl derivatives
Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
Owner:ACUACELA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com